GSK Cuts Price Of Cervarix Vaccine By 30% In Singapore
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - GlaxoSmithKline has announced the company recently reduced the price of its cervical cancer vaccine Cervarix by 30 percent in Singapore